| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Similar to Abeta1-20, this peptide binds metal ions (Cu2+, Zn2+) via histidines 6, 13, and 14. It may also interact with serum albumin and other proteins, but it has no specific receptor target. It is used primarily as a negative control.
|
|---|---|
| ln Vitro |
In cell-free assays, Abeta1-19 does not aggregate and shows no ThT fluorescence. It binds Cu2+ with an affinity similar to longer Abeta peptides (KD ~1-10 uM). It can be used to study the metal-binding N-terminal domain without interference from aggregation.
|
| ln Vivo |
When injected into animals, Abeta1-19 does not induce amyloid plaque formation, neuroinflammation, or cognitive deficits. It is a standard negative control for in vivo experiments using full-length Abeta1-42 or Abeta1-40.
|
| Enzyme Assay |
ThT aggregation assay: Dissolve Abeta1-19 in HFIP, dry, resuspend in 10 mM NaOH, dilute to 50 uM in PBS (pH 7.4) with 10 uM ThT. Incubate at 37degC for 24-72 hours, measure fluorescence at Ex/Em 440/480 nm. No increase in fluorescence is observed. For metal binding, use UV-Vis or fluorescence titration.
|
| Cell Assay |
Primary hippocampal neurons or SH-SY5Y cells are treated with Abeta1-19 (1-50 uM) for 24-72 hours. MTT or LDH assays show no significant reduction in viability. This control confirms that any neurotoxicity observed with longer Abeta peptides is due to sequences beyond residue 19.
|
| Animal Protocol |
Mice are injected ICV with Abeta1-19 (5-10 ug in 2-5 uL PBS). After 2-4 weeks, behavioral tests (Morris water maze, Y-maze) are performed. No learning or memory deficits are detected. This establishes that the N-terminal 19 residues alone are insufficient to cause Abeta pathology.
|
| ADME/Pharmacokinetics |
PK: Abeta1-19 is rapidly degraded in the brain and CSF by proteases such as neprilysin. Its half-life after ICV injection is approximately 20-30 minutes. It does not accumulate in insoluble deposits. Formulation in sterile PBS or saline with 0.1% BSA is common.
|
| Toxicity/Toxicokinetics |
Toxicity: Abeta1-19 is non-toxic at typical experimental doses. In vitro, no cytotoxicity at concentrations up to 100 uM. In vivo, no adverse effects at 50 ug ICV. Standard peptide storage: -20degC lyophilized.
|
| References | |
| Additional Infomation |
Abeta1-19 is a valuable negative control fragment in Alzheimer‘s disease research. It includes the metal-binding histidine residues but lacks the critical self-aggregation motif. The acetate salt improves solubility. This product is for research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C106H152N30O33
|
|---|---|
| Molecular Weight |
2374.52
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4211 mL | 2.1057 mL | 4.2114 mL | |
| 5 mM | 0.0842 mL | 0.4211 mL | 0.8423 mL | |
| 10 mM | 0.0421 mL | 0.2106 mL | 0.4211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
